The law of diminishing returns

Central banks to the rescue. We warned three months about a flock of doves re-turning to the markets. Their return has proved bullish for corporate bonds and equi-ties, as we expected, and vindicated our recommendation to cut exposure to cash.


  • Central banks are about to press the ‘easing’ button again. But the likes of the ECB and BoJ are facing the law of di-minishing return, i.e. it is not clear that their actions will effectively re-anchor inflation expectations at higher levels. If, by cutting rates to negative and buying loads of assets they have not succeeded, why would they now?
  • With bond yields going lower for longer, investors too face the tough reality of diminishing returns. A record amount of bonds trade below zero (YTM), and the hunt for yield is raging. Except for those predicting a global downturn – we don’t – the investment choices are clear: equities and credit remain preferred habitat.
  • Most importantly the US economy is starting to wobble. This is both a concern and a blessing. As President Trump realises that tariffs are causing self-inflicted pain, he is likely to turn less aggressive as he prepares for the US presi-dential election, in just a bit more than one year. This, and reflation policies, should keep the global economy afloat.
  • If tariffs don’t work, why not trying a currency war? We are bearish the USD, and that should be good news to EM markets.

Download the full publication below



China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.